514
Participants
Start Date
January 31, 2008
Primary Completion Date
February 28, 2009
Study Completion Date
July 31, 2009
exenatide once weekly
subcutaneous injection, 2.0mg, once a week
sitagliptin
oral tablet, 100mg, once a day
pioglitazone
oral tablet, 45mg, once a day
placebo tablet
oral tablet, once a day
placebo once weekly
subcutaneous injection, once a week
Research Site, Peoria
Research Site, Artesia
Research Site, Concord
Research Site, Encino
Research Site, Greenbrae
Research Site, La Mesa
Research Site, Orange
Research Site, Walnut Creek
Research Site, Whittier
Research Site, Colorado Springs
Research Site, Washington D.C.
Research Site, Coral Gables
Research Site, DeLand
Research Site, Melbourne
Research Site, Miami
Research Site, New Port Richey
Research Site, Decatur
Research Site, Avon
Research Site, Wichita
Research Site, Paducah
Research Site, Baton Rouge
Research Site, New Orleans
Research Site, Oxon Hill
Research Site, Boston
Research Site, Chelsea
Research Site, Ypsilanti
Research Site, Saint Louis Park
Research Site, St Louis
Research Site, Butte
Research Site, Lincoln
Research Site, Las Vegas
Research Site, New Hyde Park
Research Site, New Windsor
Research Site, New York
Research Site, Rochester
Research Site, Durham
Research Site, Statesville
Research Site, Winston-Salem
Research Site, Athens
Research Site, Cincinnati
Research Site, Dayton
Research Site, Philadelphia
Research Site, Rapid City
Research Site, Memphis
Research Site, Austin
Research Site, Dallas
Research Site, San Antonio
Research Site, Richmond
Research Site, Olympia
Research Site, Spokane
Research Site, Tacoma
Research Site, Bangalore
Research Site, Indore
Research Site, Karnāl
Research Site, Mumbai
Research Site, Pune
Research Site, Guadalajara
Research Site, Zapopan
Research Site, Mexico City
Research Site, Cuernavaca
Research Site, Monterrey
Research Site, Toluca
Lead Sponsor
Eli Lilly and Company
INDUSTRY
AstraZeneca
INDUSTRY